These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 16421163

  • 21. A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease.
    Unno N, Sakaguchi T, Nakamura T, Yamamoto N, Sugatani J, Miwa M, Konno H.
    J Surg Res; 2006 Jul; 134(1):36-43. PubMed ID: 16650870
    [Abstract] [Full Text] [Related]

  • 22. Increased platelet reactivity to the aggregatory effect of platelet activating factor, in vitro, in patients with heterozygous familial hypercholesterolaemia.
    Elisaf M, Karabina SA, Bairaktari E, Goudevenos JA, Siamopoulos KC, Tselepis AD.
    Platelets; 1999 Jul; 10(2-3):124-31. PubMed ID: 16801081
    [Abstract] [Full Text] [Related]

  • 23. Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity.
    Tambaki AP, Rizos E, Tsimihodimos V, Tselepis AD, Elisaf M.
    J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):91-5. PubMed ID: 15309245
    [Abstract] [Full Text] [Related]

  • 24. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.
    Kiortsis DN, Tsouli S, Lourida ES, Xydis V, Argyropoulou MI, Elisaf M, Tselepis AD.
    Angiology; 2005 Jun; 56(4):451-8. PubMed ID: 16079929
    [Abstract] [Full Text] [Related]

  • 25. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU.
    J Clin Oncol; 2008 Feb 01; 26(4):592-8. PubMed ID: 18235117
    [Abstract] [Full Text] [Related]

  • 26. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
    Moradi H, Pahl MV, Elahimehr R, Vaziri ND.
    Transl Res; 2009 Feb 01; 153(2):77-85. PubMed ID: 19138652
    [Abstract] [Full Text] [Related]

  • 27. The significance of human platelet-activating factor-acetylhydrolase in patients with chronic stable angina.
    Tanaseanu C, Moldoveanu E, Kosaka T, Tanaseanu S, Neagu M, Popescu LM.
    Eur J Intern Med; 2004 Aug 01; 15(5):291-297. PubMed ID: 15450986
    [Abstract] [Full Text] [Related]

  • 28. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
    Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J, Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators.
    Crit Care Med; 2004 Feb 01; 32(2):332-41. PubMed ID: 14758145
    [Abstract] [Full Text] [Related]

  • 29. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.
    Liberopoulos EN, Papavasiliou E, Miltiadous GA, Cariolou M, Siamopoulos KC, Tselepis AD, Elisaf MS.
    Perit Dial Int; 2004 Feb 01; 24(6):580-9. PubMed ID: 15559488
    [Abstract] [Full Text] [Related]

  • 30. Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice.
    Singh U, Zhong S, Xiong M, Li TB, Sniderman A, Teng BB.
    Clin Sci (Lond); 2004 Apr 01; 106(4):421-32. PubMed ID: 14717654
    [Abstract] [Full Text] [Related]

  • 31. Extracellular phospholipases in atherosclerosis.
    Karabina SA, Gora S, Atout R, Ninio E.
    Biochimie; 2010 Jun 01; 92(6):594-600. PubMed ID: 20153800
    [Abstract] [Full Text] [Related]

  • 32. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
    Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, Simons FE, Simons KJ, Cass D, Yeung J.
    N Engl J Med; 2008 Jan 03; 358(1):28-35. PubMed ID: 18172172
    [Abstract] [Full Text] [Related]

  • 33. Bovine platelet-activating factor acetylhydrolase (PAF-AH) activity related to fertility.
    Turk R, Juretić D, Geres D, Bacić G, Milesević M, Flegar-Mestrić Z, Turk N, Svetina A.
    Anim Reprod Sci; 2008 May 03; 105(3-4):344-53. PubMed ID: 17442508
    [Abstract] [Full Text] [Related]

  • 34. Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus.
    Gomes MB, Cobas RA, Nunes E, Castro-Faria-Neto HC, da Matta MF, Neves R, Tibiriçá E.
    Diabetes Res Clin Pract; 2009 Jul 03; 85(1):61-8. PubMed ID: 19464746
    [Abstract] [Full Text] [Related]

  • 35. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
    Spinowitz BS, Pratt RD, Epoetin Delta 2002 Study Group.
    Curr Med Res Opin; 2006 Dec 03; 22(12):2507-13. PubMed ID: 17166333
    [Abstract] [Full Text] [Related]

  • 36. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.
    Afzali B, Bakri RS, Bharma-Ariza P, Lumb PJ, Dalton N, Turner NC, Wierzbicki AS, Crook MA, Goldsmith DJ.
    J Nephrol; 2003 Dec 03; 16(4):540-5. PubMed ID: 14696756
    [Abstract] [Full Text] [Related]

  • 37. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.
    Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U, RUBRA Study Investigators.
    Am J Nephrol; 2008 Dec 03; 28(2):280-9. PubMed ID: 18004064
    [Abstract] [Full Text] [Related]

  • 38. Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.
    Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, Cariolou MA, Chapman MJ, Tselepis AD, Elisaf M.
    J Lipid Res; 2002 Feb 03; 43(2):256-63. PubMed ID: 11861667
    [Abstract] [Full Text] [Related]

  • 39. Adenovirus-mediated gene transfer and lipoprotein-mediated protein delivery of plasma PAF-AH ameliorates proteinuria in rat model of glomerulosclerosis.
    Iso-O N, Noto H, Hara M, Togo M, Karasawa K, Ohashi N, Noiri E, Hashimoto Y, Kadowaki T, Kimura S, Watanabe T, Tsukamoto K.
    Mol Ther; 2006 Jan 03; 13(1):118-26. PubMed ID: 16213192
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.
    Crit Care Med; 2006 Jun 03; 34(6):1661-7. PubMed ID: 16607233
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.